Our nanoconjugate displayed also a high therapeutic window, since we achieved selective CXCR4+ tumor cell uptake and high antimetastatic effect while achieving negligible distribution (as reported for T22‐GFP‐H6; Céspedes et al, 2016) or histological alterations in normal tissues (expressing or not CXCR4) with no sign of toxicity or body weight lost. This evidence concerns the gene CXCR4 and neoplasm.